Clinical trials: Immune System Disease
Autoimmune Diseases
A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
This is a Phase I Healthy volunteer study with the primary objective to evaluate the safety and pharmacokinetics profile of AX-158. The first part will evaluate single ascending dose administrations.
- Trial name
- NCT05218434
- Testing
- AX-158
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Artax Biopharma Inc
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
- Conditions
- Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
- Trial name
- NCT04268706
- Testing
- CD30.CAR-T, Fludarabine, Bendamustine
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Tessa Therapeutics
Diabetes Mellitus, Type 1
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
- Trial name
- NCT00143104
- Testing
- Inhaled insulin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Traumatic Brain Injury
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure…
- Trial name
- NCT05951777
- Testing
- Autologous HB-adMSCs, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Hope Biosciences LLC
Rheumatoid Arthritis
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in subjects with moderate to severe Rheumatoid…
- Trial name
- NCT01936181
- Testing
- Remicade (infliximab), SB2 (proposed biosimilar to infliximab)
- Where
- 2 sites in Bulgaria, Lithuania
- Volunteers
- 584 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
This multi-center, observational study will evaluate the use in clinical practice and efficacy of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01615419
- Where
- 9 sites in Greece
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Asthma
A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge
The purpose of this study is to find out how long the effect of PF-03526299 last after it is inhaled by assessing the lung function of mild asthma patients after they have been exposed to allergen
- Trial name
- NCT01299467
- Testing
- Active (PF-03526299)
- Sponsor
- Pfizer
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Asthma
A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.
The clinical trial is designed to evaluate the non-inferiority of CHF1535 100/6 µg NEXThaler versus CHF1535 100/6 µg pMDI on the onset of relief from methacholine-induced bronchospasm, in terms of pulmonary function (i.e.
- Trial name
- NCT03108534
- Testing
- CHF1535 NEXThaler, CHF1535 pMDI
- Where
- 3 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
This was a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study was to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of…
- Trial name
- NCT05526521
- Testing
- Dupilumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- Sanofi
Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
- Trial name
- NCT07220616
- Testing
- DS3790a, Combination drug
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 420 people
- Sponsor
- Daiichi Sankyo
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00523211
- Testing
- Vicriviroc
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of FIAsp (faster-acting insulin aspart) in children, adolescents and adults…
- Trial name
- NCT02035371
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Novo Nordisk A/S
Leukemia, B-cell
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety, tolerability, and pharmacokinetic profile of INS19 CAR-T cells for the treatment of patients with relapsed or refractory acute B…
- Trial name
- NCT06209671
- Testing
- INS19 CAR-T Cells
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Peripheral T Cell Lymphoma
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
- Trial name
- NCT07180771
- Testing
- BR101801
- Volunteers
- 44 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Spinal Cord Injuries, Multiple Sclerosis
GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders
The purpose of this study is to evaluate the rate of occurrence of urethral pain in female patients with neurological vesico-sphincter disorders whilst performing self-catheterization using GentleCath™ Air catheters.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Parkinsonian Disorders, Allodynia
- Trial name
- FollowAir (NCT04847609)
- Testing
- GentleCath™ Air catheter
- Sponsor
- ConvaTec Inc.
Diabetes Mellitus, Type 1, Type 1 Diabetes
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
Over 1 million patients globally currently manage their Type 1 Diabetes mellitus using continuous subcutaneous insulin infusion with an infusion set that needs to be changed every 3 days.
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Insulin-Dependent, 1
- Trial name
- FEXIS (NCT04503564)
- Testing
- coil-reinforced soft polymer indwelling cannula
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Capillary Biomedical, Inc.
Rheumatoid Arthritis
Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis
Allogeneic human umbilical cord tissue-derived stem cells will be injected intravenously once per day for 5 days is a safe and useful procedure in inducing remission of RA in patients resistant to standard DMARD therapy.
- Trial name
- NCT01985464
- Testing
- Umbilical cord mesenchymal stem cells
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Translational Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.